Showing results (521-530 of 630) with videos related to
Sort By:
Pageof 63
Journal of the American Academy of Dermatology|June 18, 2025
Focused update: Guidelines of care for the management of atopic dermatitis in adultsDawn M R Davis, Lindsy Frazer-Green, Ali Alikhan, et al.Dermatology and Therapy|May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 5, 2023
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry studyKilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre, et al.Journal of the American Academy of Dermatology|April 8, 2026
Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitisRobert Sidbury, Ali Alikhan, Lionel Bercovitch, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.JAMA Dermatology|November 3, 2021
Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group ExperienceErin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcomaP S Gill, J Wernz, D T Scadden, et al.JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.The Journal of Investigative Dermatology|June 29, 2019
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic DermatitisChris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.Pageof 63